These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

400 related items for PubMed ID: 20720189

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. An increased rate of longitudinal cognitive decline is observed in Parkinson's disease patients with low CSF Aß42 and an APOE ε4 allele.
    Shahid M, Kim J, Leaver K, Hendershott T, Zhu D, Cholerton B, Henderson VW, Tian L, Poston KL.
    Neurobiol Dis; 2019 Jul; 127():278-286. PubMed ID: 30826425
    [Abstract] [Full Text] [Related]

  • 4. CSF biomarkers and clinical progression of Parkinson disease.
    Hall S, Surova Y, Öhrfelt A, Zetterberg H, Lindqvist D, Hansson O.
    Neurology; 2015 Jan 06; 84(1):57-63. PubMed ID: 25411441
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. CSF β-Amyloid 1-42 Predicts Progression to Cognitive Impairment in Newly Diagnosed Parkinson Disease.
    Terrelonge M, Marder KS, Weintraub D, Alcalay RN.
    J Mol Neurosci; 2016 Jan 06; 58(1):88-92. PubMed ID: 26330275
    [Abstract] [Full Text] [Related]

  • 7. CSF tau and tau/Aβ42 predict cognitive decline in Parkinson's disease.
    Liu C, Cholerton B, Shi M, Ginghina C, Cain KC, Auinger P, Parkinson Study Group DATATOP Investigators, Zhang J.
    Parkinsonism Relat Disord; 2015 Mar 06; 21(3):271-6. PubMed ID: 25596881
    [Abstract] [Full Text] [Related]

  • 8. MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change.
    Vemuri P, Wiste HJ, Weigand SD, Shaw LM, Trojanowski JQ, Weiner MW, Knopman DS, Petersen RC, Jack CR, Alzheimer's Disease Neuroimaging Initiative.
    Neurology; 2009 Jul 28; 73(4):294-301. PubMed ID: 19636049
    [Abstract] [Full Text] [Related]

  • 9. Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type.
    Snider BJ, Fagan AM, Roe C, Shah AR, Grant EA, Xiong C, Morris JC, Holtzman DM.
    Arch Neurol; 2009 May 28; 66(5):638-45. PubMed ID: 19433664
    [Abstract] [Full Text] [Related]

  • 10. REM behavior disorder predicts motor progression and cognitive decline in Parkinson disease.
    Pagano G, De Micco R, Yousaf T, Wilson H, Chandra A, Politis M.
    Neurology; 2018 Sep 04; 91(10):e894-e905. PubMed ID: 30089615
    [Abstract] [Full Text] [Related]

  • 11. Neurodegenerative CSF markers in genetic and sporadic PD: Classification and prediction in a longitudinal study.
    Brockmann K, Schulte C, Deuschle C, Hauser AK, Heger T, Gasser T, Maetzler W, Berg D.
    Parkinsonism Relat Disord; 2015 Dec 04; 21(12):1427-34. PubMed ID: 26475624
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Cerebrospinal Fluid Biomarkers Predict Clinical Evolution in Patients with Subjective Cognitive Decline and Mild Cognitive Impairment.
    Sierra-Rio A, Balasa M, Olives J, Antonell A, Iranzo A, Castellví M, Bosch B, Grau-Rivera O, Fernandez-Villullas G, Rami L, Lladó A, Sánchez-Valle R, Molinuevo JL.
    Neurodegener Dis; 2016 Dec 04; 16(1-2):69-76. PubMed ID: 26560503
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Cross-Sectional and Longitudinal Cognitive Correlates of FDDNP PET and CSF Amyloid-β and Tau in Parkinson's Disease1.
    Buongiorno M, Antonelli F, Compta Y, Fernandez Y, Pavia J, Lomeña F, Ríos J, Ramírez I, García JR, Soler M, Cámara A, Fernández M, Basora M, Salazar F, Sanchez-Etayo G, Valldeoriola F, Barrio JR, Marti MJ.
    J Alzheimers Dis; 2017 Dec 04; 55(3):1261-1272. PubMed ID: 27814297
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Amyloid-β and α-synuclein cerebrospinal fluid biomarkers and cognition in early Parkinson's disease.
    Stav AL, Aarsland D, Johansen KK, Hessen E, Auning E, Fladby T.
    Parkinsonism Relat Disord; 2015 Jul 04; 21(7):758-64. PubMed ID: 25971633
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Comparing predictors of conversion and decline in mild cognitive impairment.
    Landau SM, Harvey D, Madison CM, Reiman EM, Foster NL, Aisen PS, Petersen RC, Shaw LM, Trojanowski JQ, Jack CR, Weiner MW, Jagust WJ, Alzheimer's Disease Neuroimaging Initiative.
    Neurology; 2010 Jul 20; 75(3):230-8. PubMed ID: 20592257
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.